Tyra Biosciences (NASDAQ:TYRA) Reaches New 1-Year High – Here’s What Happened

Tyra Biosciences, Inc. (NASDAQ:TYRA) hit a new 52-week high on Tuesday . The company traded as high as $37.84 and last traded at $37.01, with a volume of 575139 shares trading hands. The stock had previously closed at $36.22.

Analyst Ratings Changes

A number of equities analysts recently issued reports on TYRA shares. HC Wainwright increased their target price on shares of Tyra Biosciences from $30.00 to $45.00 and gave the company a “buy” rating in a research report on Tuesday, February 17th. Jefferies Financial Group boosted their price target on shares of Tyra Biosciences from $32.00 to $43.00 and gave the stock a “buy” rating in a research report on Tuesday, February 3rd. Wall Street Zen lowered shares of Tyra Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, January 24th. Wedbush increased their price objective on shares of Tyra Biosciences from $37.00 to $53.00 and gave the company an “outperform” rating in a report on Friday, February 13th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Tyra Biosciences in a research note on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Tyra Biosciences currently has a consensus rating of “Moderate Buy” and an average price target of $42.33.

Tyra Biosciences Price Performance

The business has a fifty day moving average of $31.80 and a 200-day moving average of $22.56. The stock has a market capitalization of $2.05 billion, a price-to-earnings ratio of -18.93 and a beta of 1.06.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings results on Monday, March 2nd. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.03). As a group, research analysts anticipate that Tyra Biosciences, Inc. will post -1.57 EPS for the current year.

Insider Activity at Tyra Biosciences

In related news, Director Robert J. More sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $25.00, for a total value of $250,000.00. Following the sale, the director directly owned 3,823,425 shares in the company, valued at $95,585,625. The trade was a 0.26% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 15.20% of the stock is owned by insiders.

Institutional Trading of Tyra Biosciences

Large investors have recently added to or reduced their stakes in the business. Commodore Capital LP grew its position in Tyra Biosciences by 226.3% in the second quarter. Commodore Capital LP now owns 3,100,000 shares of the company’s stock worth $29,667,000 after buying an additional 2,150,000 shares during the last quarter. Farallon Capital Management LLC lifted its position in shares of Tyra Biosciences by 80.7% during the 4th quarter. Farallon Capital Management LLC now owns 2,066,818 shares of the company’s stock valued at $54,337,000 after acquiring an additional 923,000 shares during the last quarter. Caligan Partners LP boosted its stake in shares of Tyra Biosciences by 266.8% during the 3rd quarter. Caligan Partners LP now owns 696,825 shares of the company’s stock worth $9,749,000 after acquiring an additional 506,875 shares in the last quarter. Boone Capital Management LLC bought a new stake in shares of Tyra Biosciences during the 4th quarter worth $10,476,000. Finally, Sio Capital Management LLC grew its holdings in shares of Tyra Biosciences by 94.5% in the 2nd quarter. Sio Capital Management LLC now owns 810,274 shares of the company’s stock worth $7,754,000 after acquiring an additional 393,657 shares during the last quarter. 84.14% of the stock is currently owned by institutional investors.

About Tyra Biosciences

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.